Immune response, clinical outcome and safety of dendritic cell vaccine in combination with cytokine-induced killer cell therapy in cancer patients.

Immune response, clinical outcome and safety of dendritic cell vaccine in combination with cytokine-induced killer cell therapy in cancer patients.

Item
http://www.wikidata.org/entity/Q37211699
Immune response, safety, and survival and quality of life outcomes for advanced colorectal cancer patients treated with dendritic cell vaccine and cytokine-induced killer cell therapyTrial watch: Dendritic cell-based anticancer therapyCytokine-Induced Killer Cells As Pharmacological Tools for Cancer Immunotherapy.Retrospective comparative study of the effects of dendritic cell vaccine and cytokine-induced killer cell immunotherapy with that of chemotherapy alone and in combination for colorectal cancer.Cytokine-induced killer cells co-cultured with dendritic cells loaded with the protein lysate produced by radiofrequency ablation induce a specific antitumor response.A Positive Role of Cytokine-Induced Killer Cell Therapy on Gastric Cancer Therapy in a Chinese Population: A Systematic Meta-Analysis.The combination of dendritic cells-cytotoxic T lymphocytes/cytokine-induced killer (DC-CTL/CIK) therapy exerts immune and clinical responses in patients with malignant tumors.Clinical outcome of immunotherapy with dendritic cell vaccine and cytokine-induced killer cell therapy in hepatobiliary and pancreatic cancer.Dendritic cell vaccine and cytokine-induced killer cell therapy for the treatment of advanced non-small cell lung cancerFeasibility study of DCs/CIKs combined with thoracic radiotherapy for patients with locally advanced or metastatic non-small-cell lung cancerNatural killer cell regulation - beyond the receptors.Immunotherapy of patient with hepatocellular carcinoma using cytotoxic T lymphocytes ex vivo activated with tumor antigen-pulsed dendritic cells.Clinical value of Pro-GRP and T lymphocyte subpopulation for the assessment of immune functions of lung cancer patients after DC-CIK biological therapy.CD40L coding oncolytic adenovirus allows long-term survival of humanized mice receiving dendritic cell therapyChemotherapy combined with dendritic cell vaccine and cytokine-induced killer cells in the treatment of colorectal carcinoma: a meta-analysisExosomes derived from rAAV/AFP-transfected dendritic cells elicit specific T cell-mediated immune responses against hepatocellular carcinoma
P2860

Immune response, clinical outcome and safety of dendritic cell vaccine in combination with cytokine-induced killer cell therapy in cancer patients.

Item
http://www.wikidata.org/entity/Q37211699
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 04 June 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Immune response, clinical outc ...... ll therapy in cancer patients.
@en
Immune response, clinical outc ...... ll therapy in cancer patients.
@nl
type
label
Immune response, clinical outc ...... ll therapy in cancer patients.
@en
Immune response, clinical outc ...... ll therapy in cancer patients.
@nl
prefLabel
Immune response, clinical outc ...... ll therapy in cancer patients.
@en
Immune response, clinical outc ...... ll therapy in cancer patients.
@nl
P1433
P1476
P2093
P2860
P304
P31
P356
P433
P478
P577
P5875
P698
P932
P356
P1433
P1476
Immune response, clinical outc ...... ll therapy in cancer patients.
@en
P2093
P2860
P304
P31
P356
P433
P478
P577
P5875
P698
P932